Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer

Oncotarget

Volumn 6, Issue 17, 2015, Pages 14913-14925

  Liu, Hao ^a   Gu, Yixue ^a   Wang, Hongsheng ^b   Yin, Jiang ^a   Zheng, Guopei ^a   Zhang, Zhijie ^a   Lu, Minyin ^a   Wang, Chenkun ^a   He, Zhimin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

FTY720; Non small cell lung cancer; PP2A; SET oncoprotein

Indexed keywords

CHAPERONE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FINGOLIMOD; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN KINASE B; SET PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL; CANCER STAGING; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; GENETICS; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; MOUSE; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FINGOLIMOD HYDROCHLORIDE; HISTONE CHAPERONES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM STAGING; PROGNOSIS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84934282103     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3818     Document Type: Article

References (44)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
2. Ke Z, He W, Lai Y, Guo X, Chen S, Li S, Wang Y and Wang L. Overexpression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. Oncotarget. 2014; 5:9410.
3. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R and Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014; 5:1392-1433.
4. Abrantes JL, Tornatore TF, Pelizzaro-Rocha KJ, de Jesus MB, Cartaxo RT, Milani R and Ferreira-Halder CV. Crosstalk between kinases, phosphatases and miRNAs in cancer. Biochimie. 2014; 107PB:167-187.
5. Aceto N and Bentires-Alj M. Targeting protein-tyrosine phosphatases in breast cancer. Oncotarget. 2012; 3:514-515.
6. Zhang Q and Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Res. 2012; 2012:659649.
7. Perrotti D and Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013; 14:e229-238.
8. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC and Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell. 2004; 5:127-136.
9. Janssens V, Goris J and Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005; 15:34-41.
10. Ruvolo PP, Qui Y, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M and Kornblau SM. Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. 2011; 25:1711-1717.
11. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY and Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2008; 283:1882-1892.
12. Van Kanegan MJ, Adams DG, Wadzinski BE and Strack S. Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt. J Biol Chem. 2005; 280:36029-36036.
13. Letourneux C, Rocher G and Porteu F. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. Embo J. 2006; 25:727-738.
14. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007; 130:51-62.
15. Arnold HK and Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev. 2008; 27(2):147-158.
16. Eichhorn PJ, Creyghton MP and Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 2009; 1795:1-15.
17. Schonthal AH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett. 2001; 170(1):1-13.
18. Lv P, Wang Y, Ma J, Wang Z, Li JL, Hong CS, Zhuang Z and Zeng YX. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair. Oncotarget. 2014; 5:7512-7524.
19. Li M, Makkinje A and Damuni Z. The myeloid leukemiaassociated protein SET is a potent inhibitor of protein phosphatase 2A. Journal of Biological Chemistry. 1996; 271:11059-11062.
20. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I and Iqbal K. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett. 2011; 585:2653-2659.
21. Cervoni N, Detich N, Seo SB, Chakravarti D and Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem. 2002; 277:25026-25031.
22. Kandilci A, Mientjes E and Grosveld G. Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937. Leukemia. 2004; 18:337-340.
23. Almeida LO, Garcia CB, Matos-Silva FA, Curti C and Leopoldino AM. Accumulated SET protein up-regulates and interacts with hnRNPK, increasing its binding to nucleic acids, the Bcl-xS repression, and cellular proliferation. Biochem Biophys Res Commun. 2014; 445:196-202.
24. Avet C, Garrel G, Denoyelle C, Laverriere JN, Counis R, Cohen-Tannoudji J and Simon V. SET protein interacts with intracellular domains of the gonadotropin-releasing hormone receptor and differentially regulates receptor signaling to cAMP and calcium in gonadotrope cells. J Biol Chem. 2013; 288:2641-2654.
25. Cristobal I, Rincon R, Manso R, Carames C, Zazo S, Madoz-Gurpide J, Rojo F and Garcia-Foncillas J. Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2015; 21:347-356.
26. Cristóbal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ and Odero MD. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012; 97:543-550.
27. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J and Curti C. SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification. Oral oncology. 2012; 48:1106-1113.
28. Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ and Sears RC. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci U S A. 2014; 111:9157-9162.
29. Liu H, Gu Y, Yin J, Zheng G, Wang C, Zhang Z, Deng M, Liu J, Jia X and He Z. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. Cell Signal. 2014; 26:2710-2720.
30. Sobral LM, Sousa LO, Coletta RD, Cabral H, Greene LJ, Tajara EH, Gutkind JS, Curti C and Leopoldino AM. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. Mol Cancer. 2014; 13:32.
31. Rincon R, Cristobal I, Zazo S, Arpi O, Menendez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, Garcia-Foncillas J, Madoz-Gurpide J and Rojo F. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget. 2015; 6:4299-4314.
32. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A and Uttam A. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer cell. 2005; 8:355-368.
33. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013; 122:1923-1934.
34. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013; 5:105-121.
35. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA and Vitek MP. Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011; 30:2504-2513.
36. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T and Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006; 66:221-231.
37. Seshacharyulu P, Pandey P, Datta K and Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013; 335:9-18.
38. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J and Evans GA. Alterations of the PPP2R1B gene in human lung and colon cancer. Science. 1998; 282(5387):284-287.
39. Ruediger R, Pham HT and Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene. 2001; 20:1892-1899.
40. Ruediger R, Ruiz J and Walter G. Human cancer-associated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice. Mol Cell Biol. 2011; 31:3832-3844.
41. Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP and Odero MD. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia. 2014; 28:1915-1918.
42. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007; 117:2408-2421.
43. Neviani P and Perrotti D. SETting OP449 into the PP2AActivating Drug Family. Clin Cancer Res. 2014; 20:2026-2028.
44. Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez C, Christensen DJ, Sheppard B and Sears RC. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res. 2014; 12:924-939.